Medicare supplemental policies can help with cost shares related to many aspects of your health care. Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved both VYNDAQEL ® (tafamidis meglumine) and VYNDAMAX™ (tafamidis) for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. VYNDAMAX was developed for patient convenience; VYNDAQEL and VYNDAMAX are not substitutable on a per milligram basis. Download the enrollment form. VYNDAQEL® (tafamidis meglumine) Capsules and VYNDAMAX™ (tafamidis) Capsules If you are already enrolled, Our dedicated Patient Support Navigators are ready to help youPatients should always ask their doctors for medical advice about adverse events. Share your location or enter your city or zip code to find studies near you.Copyright © 2002-2020 Pfizer Inc. All rights reserved. Links to other sites are provided as a resource to our visitors. Sorry, you need to enable JavaScript to visit this website. Financial assistance options When you've decided VYNDAMAX is appropriate for your patient, VyndaLink can help VyndaLink can help connect your patients with potential financial assistance Offer is not valid for cash-paying patients. U.S. FDA Approves VYNDAQEL® and VYNDAMAX™ for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease PRESS RELEASE Businesswire May. The Pfizer Patient Assistance Program is a joint program of Pfizer Inc. and the Pfizer Patient Assistance FoundationConnect patients to support groups and online communities that can offer additional supportDirect patients to advocacy organizations and educational resourcesRefer patients to independent organizations that can help eligible individuals find rides and lodging for treatment-related appointmentsOutreach from Patient Support Navigators to patients to discuss changes in their treatment or coverage that might impact their support needs*Patients who are interested must opt in to the Patient Support Navigator program. Patients are responsible for as little as a $0 monthly co-payment based upon program utilization. Financial and insurance assistance. VYNDAQEL was granted Orphan Drug Designation for ATTR-CM in both the EU and U.S. in 2012 and in Japan in 2018. Under this fund, HealthWell can assist with premium costs. The value of this co-pay card is limited to a maximum of $60,000 per calendar year.This co-pay card is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plan or other private health or pharmacy benefit programs.You must deduct the value of this co-pay card from any reimbursement request submitted to your private insurance plan, either directly by you or on your behalf.You are responsible for reporting use of the co-pay card to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the co-pay card, as may be required. We can also help you better understand your coverage and benefits, including pharmacy benefits.If you have Medicare/Medicare Part D or other government insurance plans, we can help identify financial support options that may help cover the cost of your medicine.If you need help with the cost of your medicine and may be eligible, we can refer you to Medicare Extra Help or identify alternate sources of funding.If support through an alternate funding source is not available, you may be eligible to receive VYNDAMAX at no cost through the Pfizer Patient Assistance Program. Visit The product information provided in this site is intended for residents of the United States. VYNDAQEL and VYNDAMAX are not substitutable on a per milligram basis. Vyndamax; Vyndaqel; Fund Definition. Eligible patients can register for valuable savings offers for nearly 40 brand name medications. VYNDAQEL® (tafamidis meglumine) Capsules and VYNDAMAX™ (tafamidis) Capsules To find out if you’re eligible, call us at If you don’t have health insurance coverage, we can connect you to potential resources that may help cover the cost of VYNDAMAX.We can check to see if you’re eligible for Medicaid and we can tell you how to contact Medicaid to apply.If you do not have insurance or prescription coverage and you are unable to afford your medicine, we may be able to help. This information—including product information—is intended only for residents of the United States. Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved both VYNDAQEL ® (tafamidis meglumine) and VYNDAMAX™ (tafamidis) for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.